ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
